Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
08 févr. 2024 07h00 HE
|
Adverum Biotechnologies, Inc.
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and...
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing
05 févr. 2024 07h45 HE
|
Adverum Biotechnologies, Inc.
- Financing led by TCGX with participation from new and existing investors including 5AM Ventures, Commodore Capital, Frazier Life Sciences, Logos Capital, Samsara BioCapital, Venrock Healthcare...
Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024
01 févr. 2024 17h30 HE
|
Adverum Biotechnologies, Inc.
- Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47th Annual Meeting of the Macula Society, with...
Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer
29 janv. 2024 08h00 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society
07 déc. 2023 16h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference
28 nov. 2023 16h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights
09 nov. 2023 16h05 HE
|
Adverum Biotechnologies, Inc.
- Announced preliminary aflibercept protein levels from the on-going Phase 2 LUNA trial, suggesting that both doses are within the therapeutically active range and consistent with aflibercept levels...
Adverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of Directors
06 nov. 2023 08h00 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023
04 nov. 2023 17h54 HE
|
Adverum Biotechnologies, Inc.
- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction...
Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 Trial
26 sept. 2023 16h05 HE
|
Adverum Biotechnologies, Inc.
- Initial aflibercept protein levels in LUNA suggest Ixo-vec at both the 2E11 and 6E10 doses delivers aflibercept protein levels within the therapeutically active range - - Ixo-vec has been...